Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, 40% of alopecia areata patients using topical 2% tofacitinib ointment achieved greater than 50% improvement in hair regrowth after six months, showing significant efficacy compared to controls, with no serious adverse effects reported.

In this study, researchers analyzed over 5,000 T cells per sample using scRNA+TCR-seq technology and found that dual TCR Tregs are present in high proportions across various mouse tissues, showing unique TCR pairing patterns, V(D)J usage, and mRNA expression compared to single TCR Tregs.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This study reported that the combination of tridax procumbens and ginger juice improved antioxidant activity and protected against liver damage induced by paracetamol in rats, suggesting a potent hepatoprotective effect.

In this institution-based randomized trial, oral betamethasone mini-pulse therapy for alopecia areata showed a faster therapeutic response compared to oral tofacitinib, as measured by trichoscopic changes and achievement of 50% hair regrowth.

This study observed that oral tofacitinib was effective and safe for treating alopecia areata in paediatric patients, with 82% of pre-adolescent participants experiencing hair regrowth and 64% showing significant improvement in their hair loss severity scores.

This case report highlights that Tjalma Syndrome may present as a main symptom of systemic lupus erythematosus and should be considered in patients with ascites, pleural effusions, and elevated CA-125 levels.

This study supports the traditional use of T. procumbens for diabetes treatment, showing improvements in body weight and glucose tolerance with no toxicity signs in normal rats.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

In this study, two patients with alopecia universalis continued using tofacitinib during active COVID-19 infection and showed no worsening of their illness, despite potential concerns about immunosuppression.

This report describes eleven cases of thallium poisoning in individuals who consumed tortillas made from barley mixed with thallium sulphate, leading to symptoms including tingling, abdominal pain, vomiting, and limb weakness.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.

This study found that Tofacitinib effectively improved hair regrowth in patients with Alopecia Areata, with most participants showing a significant change in their Severity of Alopecia Tool scores.

Tiger tail banding and hair abnormalities are reliable indicators for diagnosing trichothiodystrophy.

Adding diltiazem to a beta blocker can cause dangerously slow heart rates.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

This study focused on Shaykh Abbas Kuta Karang, a prominent 19th-century Malay scholar, and his influential medical manuscript, Al-Rahmah fi al-Tib wa al-Hikmah, which documents traditional Malay medical knowledge spanning human anatomy, dietary principles, and treatments for various illnesses.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

This review explores the therapeutic potential and diverse pharmacological properties of the tree Tectona grandis, highlighting its anti-ulcerogenic, antihyperglycemic, antifungal, and other activities, as well as recent advancements in using its extracts for metal nanoparticle synthesis with antimicrobial applications.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

In this study, oral tofacitinib was associated with significant hair regrowth in patients with alopecia areata, achieving over 50% reduction in Severity of Alopecia Tool scores, with mild side effects.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

This study introduced a new spectrofluorometric method using a synthesized organic fluorophore to effectively analyze darolutamide and thalidomide in pharmaceutical preparations and biofluids.

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.

In this study, two patients with refractory juvenile dermatomyositis improved clinically and in disease activity after receiving the JAK inhibitor tofacitinib, showing potential effects in managing the condition.

This study found that compounds from *Tectona grandis* leaves showed moderate inhibition of steroid 5α-reductase, a factor in androgenetic alopecia, and exhibited anti-inflammatory properties by inhibiting nitric oxide and pro-inflammatory cytokines IL-1β and IL-6 in vitro, suggesting potential dual-action benefits for AGA management.

TAK-279 effectively reduces psoriasis symptoms and is safe.

TLR7-based compounds may help manage chemotherapy-induced hair loss.